Clinical Study
Diagnostic Role of 18F-FECH-PET/CT Compared with Bone Scan in Evaluating the Prostate Cancer Patients Referring with Biochemical Recurrence
| | No. | Age | GS | Prior T | PSA | Ongoing T | FD | FECH-PET | BS | Interval |
| | 1 | 79 | n/a | RP | 3.01 | NIL | LN-M | LN-M | Neg | 4 | | 2 | 64 | 7 | RP + HIFU | 6.5 | NIL | LN-M | LN-M | Neg | 14 | | 3 | 75 | n/a | RP + AHT | 7.7 | NIL | LN-M | LN-M | Neg | 24 | | 4 | 74 | 5 | RTx | 19 | AHT | LN-M | LN-M | FP | 0 | | 5 | 60 | 3 | RP | 0.4 | NIL | LN-M | LN-M | Neg | 35 | | 6 | 63 | 8 | AHT | 4.8 | NIL | LR | LR | Neg | 2 | | 7 | 69 | 9 | RP + AHT | 1.9 | NIL | LR | LR | Neg | 11 | | 8 | 76 | n/a | RP | 0.8 | NIL | PM | PM | Neg | 18 | | 9 | 70 | 7 | RP + RTx | 3.6 | NIL | NDR | Neg | Neg | 38 | | 10 | 59 | 9 | RP + RTx | 0.3 | NIL | NDR | Neg | Neg | 14 | | 11 | 85 | 7 | RTx | 1.56 | NIL | NDR | Neg | Neg | 9 | | 12 | 65 | 8 | RP | 0.66 | NIL | NDR | Neg | Neg | 3 | | 13 | 73 | n/a | RP | 0.4 | NIL | NDR | Neg | Neg | 1 | | 14 | 79 | n/a | RP | 0.4 | NIL | NDR | Neg | Neg | 1 | | 15 | 68 | n/a | RP + RTx | 0.5 | NIL | NDR | Neg | FP | 25 | | 16 | 68 | 7 | RP + RTx | 1.6 | NIL | NDR | Neg | Neg | 4 | | 17 | 69 | 7 | RP + RTx | 1.9 | NIL | NDR | Neg | Neg | 3 | | 18 | 68 | 9 | RP + RTx | 0.9 | NIL | NDR | Neg | Neg | 42 | | 19 | 80 | n/a | RTx | 0.3 | NIL | NDR | Neg | Neg | 25 | | 20 | 63 | 9 | AHT | 13.1 | AHT | OSS | OSS | OSS | 22 | | 21 | 70 | 7 | RP | 1 | NIL | OSS | OSS | OSS | 45 | | 22 | 71 | 7 | RP + RTx | 12.9 | NIL | OSS | OSS | OSS | 5 | | 23 | 77 | 8 | RP + RTx | 1.8 | RTx | OSS | OSS | OSS | 24 | | 24 | 69 | 8 | RP + RTx | 1.7 | NIL | OSS | OSS | OSS | 9 | | 25 | 56 | 9 | RP + RTx + AHT | 6.7 | Docetaxel | OSS | OSS | OSS | 4 | | 26 | 71 | 8 | RTx | 2.9 | AHT | OSS | OSS | OSS | 15 | | 27 | 59 | 8 | RTx | 3.63 | NIL | OSS | OSS | OSS | 11 | | 28 | 61 | 8 | RP | 1.9 | AHT | OSS | OSS | OSS | 6 | | 29 | 73 | 9 | RP | 21 | NIL | OSS + LN-M | OSS + LN-M | OSS | 7 | | 30 | 71 | 8 | RTx | 5 | AHT | OSS + PM | OSS + PM | OSS | 45 | | 31 | 66 | 7 | RP + RTx | 21 | Docetaxel | OSS + LN-M | LN-M FN | OSS | 14 | | 32 | 64 | 7 | RP + AHT | 1 | AHT | OSS + LN-M | LN-M FN | OSS | 7 | | 33 | 76 | 7 | RP | 5.6 | NIL | OSS | FN | OSS | 3 | | 34 | 67 | 7 | RTx | 4.5 | NIL | OSS | OSS | FN | 18 | | 35 | 65 | 7 | RP | 12.1 | NIL | OSS | OSS | OSS | 2 | | 36 | 62 | 9 | AHT | 14 | AHT | OSS | OSS | OSS | 11 | | 37 | 77 | n/a | RP + RTx | 4 | NIL | OSS | OSS | OSS | 5 |
|
|
PR: radical prostatectomy, RTx: radiation therapy, CTx: chemotherapy, NIL: nothing, AHT: hormone/androgen deprivation therapy, LN-M: lymph node metastasis, OSS: bone metastasis, PM: pulmonary metastasis, Neg: negative finding.
|
